Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | FBP1 | P09467 | 12/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6122455 | 0.79 | TSHR (0.70) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL25518523 | 0.78 | CYP2D6 (0.51) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL6127516 | 0.77 | CYP2D6 (0.82) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL6127693 | 0.77 | CYP2D6 (0.82) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL8692307 | 0.75 | CYP2D6 (0.56) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL2012755 | 0.75 | KMT2A (0.56) | TSHRFBP1ALDH1A1KMT2A | |
| SCHEMBL2006628 | 0.75 | FBP1 (0.48) | CYP2C9TSHRFBP1ALDH1A1 | |
| SCHEMBL2008042 | 0.75 | FBP1 (0.53) | CYP2C9CYP2C19TSHRFBP1ALDH1A1 | |
| SCHEMBL2008078 | 0.75 | SMN1; SMN2 (0.55) | FBP1KMT2A | |
| SCHEMBL2007912 | 0.75 | FBP1 (0.53) | CYP2C9CYP2C19TSHRFBP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964633-B2 | such as N,N'-[hexane-1,6-diylbis(iminocarbonyl)]bis(3-chlorobenzenesulfonamide), used as Fructose-1,6-bisphosphatase inhibitors; metabolic disorders such as diabetes | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | claimed |
| EP-2081889-B1 | SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | claimed |
| US-20080085928-A1 | Sulfonamide derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-10 | — | — | US | claimed |
| US-7964633-B2 | such as N,N'-[hexane-1,6-diylbis(iminocarbonyl)]bis(3-chlorobenzenesulfonamide), used as Fructose-1,6-bisphosphatase inhibitors; metabolic disorders such as diabetes | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2081889-B1 | SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2081889-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20080085928-A1 | Sulfonamide derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-10 | — | — | US | disclosed |
| WO-2008037628-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085928-A1 | Sulfonamide derivatives | SULT2A1, SULT1A1, SULT1E1 | CYP2D6 70/4885CYP2C9 49/4885CYP2C19 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.